Rezatapopt Shows Promise in Reactivating Mutant p53 in Advanced Solid Tumors

A first-in-human clinical trial published in the New England Journal of Medicine on February 26, 2026, demonstrates that the investigational drug rezatapopt selectively reactivates mutant p53 in patients with advanced solid tumors. PMV Pharma announced the publication of the data, highlighting a potential new approach to cancer treatment.

Understanding p53 and its Role in Cancer

The p53 gene is often referred to as the “guardian of the genome” because it plays a critical role in preventing cancer. It functions as a tumor suppressor, meaning it normally helps to regulate cell growth and prevent the development of tumors. Although, in many cancers, the p53 gene is mutated, rendering it non-functional. This loss of p53 function allows cancer cells to grow and proliferate unchecked.

How Rezatapopt Works

Rezatapopt is designed to selectively restore the function of mutant p53 proteins. Unlike traditional approaches that often target rapidly dividing cells, rezatapopt aims to address the underlying genetic defect driving cancer growth. The trial data suggests that rezatapopt can reactivate these mutant p53 proteins, potentially restoring their tumor-suppressing capabilities.

Key Findings from the First-in-Human Trial

The Phase 1 trial evaluated the safety and efficacy of rezatapopt in patients with advanced solid tumors harboring mutant p53. The study assessed the drug’s ability to reactivate mutant p53 and its impact on tumor response. Even as the trial primarily focused on safety, initial data indicated evidence of target engagement and potential clinical activity in some patients. Further research is needed to confirm these findings and determine the optimal dosage and treatment regimens.

Implications for Cancer Treatment

The findings from this first-in-human trial represent a significant step forward in the development of targeted therapies for cancers with mutant p53. If further studies confirm these results, rezatapopt could offer a new treatment option for patients who have limited or no effective therapies available. The selective reactivation of mutant p53 could potentially lead to more effective and less toxic cancer treatments.

Looking Ahead

Ongoing and future clinical trials will continue to evaluate the safety and efficacy of rezatapopt in larger patient populations and across a wider range of cancer types. Researchers will also investigate potential combinations of rezatapopt with other cancer therapies to enhance its effectiveness. The publication in the New England Journal of Medicine underscores the growing interest in targeting p53 mutations as a promising strategy in the fight against cancer. NEJM This Week